Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs
Identifieur interne : 000598 ( PascalFrancis/Checkpoint ); précédent : 000597; suivant : 000599Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs
Auteurs : Jonathan P. Wong [Canada] ; Les P. Nagata [Canada] ; Mary E. Christopher [Canada] ; Andres M. Salazar [États-Unis] ; Roderic M. K. Dale [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0198136Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs</title><author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oncovir Inc</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Oligos Etc. Inc</s1><s2>Wilsonville, OR</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Oregon</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0198136</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 06-0198136 INIST</idno><idno type="RBID">Pascal:06-0198136</idno><idno type="wicri:Area/PascalFrancis/Corpus">000521</idno><idno type="wicri:Area/PascalFrancis/Curation">000469</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000598</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000598</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs</title><author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Defence R&D Canada</wicri:noRegion></affiliation></author><author><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oncovir Inc</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">District de Columbia</region></placeName></affiliation></author><author><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Oligos Etc. Inc</s1><s2>Wilsonville, OR</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Oregon</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term><term>Chemoprophylaxis</term><term>Nucleic acid</term><term>Viral disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chimioprophylaxie</term><term>Aigu</term><term>Acide nucléique</term><term>Virose</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>23</s2></fA05><fA06><s2>17-18</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Vaccines and immunisation. Based on the fourth world congress on vaccines and immunisation, Tsukuba Science City/Tokyo, Japan, 30 september-3 october 2004</s1></fA09><fA11 i1="01" i2="1"><s1>WONG (Jonathan P.)</s1></fA11><fA11 i1="02" i2="1"><s1>NAGATA (Les P.)</s1></fA11><fA11 i1="03" i2="1"><s1>CHRISTOPHER (Mary E.)</s1></fA11><fA11 i1="04" i2="1"><s1>SALAZAR (Andres M.)</s1></fA11><fA11 i1="05" i2="1"><s1>DALE (Roderic M. K.)</s1></fA11><fA12 i1="01" i2="1"><s1>KURSTAK (Edouard)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Defence R&D Canada</s1><s2>Suffield, Alherta</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Oncovir Inc</s1><s2>Washington, DC</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Oligos Etc. Inc</s1><s2>Wilsonville, OR</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA15 i1="01"><s1>Infections Control World Organization, Faculty of Medicine, University of Montreal</s1><s2>Montreal, Que., H3C 3J7</s2><s3>CAN</s3><sZ>1 aut.</sZ></fA15><fA18 i1="01" i2="1"><s1>Infections Control World Organization (ICWO)</s1><s3>CAN</s3><s9>patr.</s9></fA18><fA20><s1>2266-2268</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000133094560440</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>10 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0198136</s0></fA47><fA60><s1>P</s1><s2>C</s2></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Acute respiratory virus infections such as SARS and pandemic influenza are highly contagious diseases that cause global crisis, and inflict severe human mortality and morbidity. Vaccines against these viruses are either unavailable or do not provide adequate protection. In the absence of effective vaccines, nucleic acid-based immunomodulators have the potential to offer effective, broad-spectrum protection against these deadly pathogens. Poly ICLC and CpG oligonucleotides are promising gene-based drugs which have been shown in animal studies to protect against acute respiratory virus infections. Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator. When encapsulated in liposomes, poly ICLC offers complete protection (100% survival rate in pretreated group versus 0% survival in control group) against a lethal respiratory challenge of influenza A virus in mice. This antiviral effect has been shown to persist for up to 3 weeks post-drug treatment. Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine. CpG oligos in liposomes also provided high level of protection against the lethal influenza challenge. Together, these studies suggest nucleic acid-based immunomodulators are promising antiviral agents which can offer effective and non-specific protection against acute respiratory virus infections.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Chimioprophylaxie</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Chemoprophylaxis</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Quimioprofilaxis</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Aigu</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Acute</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Agudo</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Acide nucléique</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nucleic acid</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Acido nucleico</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Virose</s0><s5>14</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Viral disease</s0><s5>14</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Virosis</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>121</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA><pR><fA30 i1="01" i2="1" l="ENG"><s1>World Congress on Vaccines and Immunisation</s1><s2>4</s2><s3>Tokyo JPN</s3><s4>2004-09-30</s4></fA30></pR></standard></inist><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>District de Columbia</li><li>Oregon</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P." last="Wong">Jonathan P. Wong</name></noRegion><name sortKey="Christopher, Mary E" sort="Christopher, Mary E" uniqKey="Christopher M" first="Mary E." last="Christopher">Mary E. Christopher</name><name sortKey="Nagata, Les P" sort="Nagata, Les P" uniqKey="Nagata L" first="Les P." last="Nagata">Les P. Nagata</name></country><country name="États-Unis"><region name="District de Columbia"><name sortKey="Salazar, Andres M" sort="Salazar, Andres M" uniqKey="Salazar A" first="Andres M." last="Salazar">Andres M. Salazar</name></region><name sortKey="Dale, Roderic M K" sort="Dale, Roderic M K" uniqKey="Dale R" first="Roderic M. K." last="Dale">Roderic M. K. Dale</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000598 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000598 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:06-0198136
|texte= Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs
}}
| This area was generated with Dilib version V0.6.33. |  |